PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Results 1 - 20 of 128 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar Reddragyn (69.58) Submitted: 3/28/2015 8:42:32 PM : Outperform Start Price: $7.07 PDLI Score: -1.27

Mag Inv Plus
HYLP

Recs

0
Member Avatar derbydog85 (47.44) Submitted: 3/14/2015 12:23:13 AM : Underperform Start Price: $7.31 PDLI Score: +4.68

Patents end soon. So goes the patents, so goes their profits.

Recs

0
Member Avatar savolk77 (55.37) Submitted: 3/4/2015 1:12:05 AM : Outperform Start Price: $7.07 PDLI Score: +0.38

Nice earnings history last few years, solid fundamentals, could be ready to pop.

Recs

1
Member Avatar jason418 (< 20) Submitted: 1/4/2015 2:14:57 AM : Outperform Start Price: $7.46 PDLI Score: -7.86

Currently, PDLI has about two years of decent earning to continue to build a portfolio of intellectual property and interest income. Over the last three years, they have negotiated an average of 4 deals per year with other companies and have averaged an impressive IRR. The uncertainty priced into the stock is based upon whether or not they can continue that same performance. I believe the track record is good so far and is an excellent indicator of things to come. Despite some debt, they're in an excellent financial position to capitalize on many opportunities. The biggest downside is the possibility that they may reduce or cut their dividend altogether. I think if you're a long-term investor, however, you'll see their current strategy payoff in the form of solid revenue growth. You just have to ride out a couple years of investments.

Recs

0
Member Avatar TrackMagicFormul (86.57) Submitted: 10/8/2014 10:15:20 AM : Outperform Start Price: $6.87 PDLI Score: -41.06

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Nov 14 $6.00 strike at 15¢ has 21% discount and 20% annualized return.

Recs

0
Member Avatar aa119634 (< 20) Submitted: 9/24/2014 12:43:14 PM : Outperform Start Price: $7.33 PDLI Score: -9.04

On-going royalties of .60 per share should be maintainable. With no price appreciation you earn 7.8% just sitting with the stock. If it gets close to 9 consider selling and buying back again if it gets under 8.

Recs

0
Member Avatar johnclanaro (< 20) Submitted: 8/19/2014 8:47:46 PM : Outperform Start Price: $9.09 PDLI Score: -28.03

2d qtr beats on eps, beats on revenue. yields 6.44% at a price of 9.55 per share.

Recs

0
Member Avatar Cabzx (58.46) Submitted: 8/17/2014 1:43:15 PM : Outperform Start Price: $8.97 PDLI Score: -27.67

The large Debt/Equity maybe a turnoff for some, but the company has solid revenues, consistently beating the industry. It has a very high coverage and makes for a consistent buy.

Recs

0
Member Avatar Orthonormal (94.43) Submitted: 3/12/2014 10:32:22 AM : Outperform Start Price: $7.63 PDLI Score: -19.57

Magic Formula pick 3/21/2012
renewed 3/12/2014

Recs

0
Member Avatar NorbertV (< 20) Submitted: 1/28/2014 5:12:41 PM : Outperform Start Price: $8.21 PDLI Score: -31.89

2 years 33% gain plus excellent dividend. P/E at 5 right now no reason it shouldn't continue up.

Recs

0
Member Avatar lnlrmtg (39.99) Submitted: 1/8/2014 2:31:12 AM : Outperform Start Price: $7.96 PDLI Score: -25.42

fundamentals

Recs

0
Member Avatar Haugurafpeningum (29.09) Submitted: 1/5/2014 2:24:06 PM : Outperform Start Price: $7.94 PDLI Score: -25.21

porte and zz 1

Recs

0
Member Avatar Stregachess (< 20) Submitted: 10/3/2013 12:07:46 AM : Underperform Start Price: $7.18 PDLI Score: +25.71

Analyst love this stock but the IP can't be controlled they are in for a rough ride. Without patent protection it's all just a dream.

Recs

0
Member Avatar tgainesphd (50.59) Submitted: 4/18/2013 8:01:13 PM : Outperform Start Price: $6.51 PDLI Score: -27.08

Good growth potential.

Recs

0
Member Avatar Aquinas31 (27.65) Submitted: 4/3/2013 4:56:19 PM : Outperform Start Price: $6.37 PDLI Score: -23.89

Dividends going up, probably hits 8+ by 4th quarter

Recs

0
Member Avatar dunloggin (66.23) Submitted: 2/5/2013 1:45:05 PM : Outperform Start Price: $5.78 PDLI Score: -16.37

Dividend paying stock.

Recs

0
Member Avatar pdhaag (65.31) Submitted: 10/15/2012 9:18:41 PM : Underperform Start Price: $6.82 PDLI Score: +41.05

Most of it's patents are set to expire between 2014 and 2017, at which point revenue will drop dramatically. It's only a matter of time.

Recs

1
Member Avatar FoxForce5contest (< 20) Submitted: 8/18/2012 9:18:30 PM : Outperform Start Price: $6.03 PDLI Score: -30.44

on 8-18-12 Momentum21 picked PDLI

Recs

0
Member Avatar myfairshare (< 20) Submitted: 8/17/2012 6:04:53 PM : Outperform Start Price: $6.03 PDLI Score: -30.44

I think the royalties are the best position to be in, for the pharmaceutical plays.

Recs

0
Member Avatar SamsaricSufferer (52.06) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $5.52 PDLI Score: -24.98

Biotech with solid pipeline

Featured Broker Partners


Advertisement